Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 2:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 3,908 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cancer Prostate Clear all
Active, not recruiting Not applicable Interventional

Proton Boost in Prostate Cancer

NCT03564275
View directory record Official record
Conditions
Cancer of the Prostate
Interventions
Proton Boost
Radiation
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2033
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 31, 2025 · Synced Oct 20, 2026, 2:42 PM EDT
Completed Phase 2 Interventional Results available

Eflornithine in Treating Patients At High Risk of Developing Prostate Cancer

NCT00006101
View directory record Official record
Conditions
Prostate Cancer
Interventions
eflornithine, Placebo
Drug
Lead sponsor
Thomas E. Ahlering
Other
Eligibility
35 Years to 70 Years · Male only
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2012
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated May 14, 2018 · Synced Oct 20, 2026, 2:42 PM EDT
Completed Phase 3 Interventional

Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer

NCT00030654
View directory record Official record
Conditions
Prostate Cancer
Interventions
bicalutamide, docetaxel, doxorubicin hydrochloride, estramustine phosphate sodium, flutamide, ketoconazole, paclitaxel, releasing hormone agonist therapy, vinblastine sulfate
Drug
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years to 120 Years · Male only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
75
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 63 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Oct 20, 2026, 2:42 PM EDT
Completed Phase 2 Interventional

Calcitriol and Dexamethasone in Treating Patients With Prostate Cancer Who Have Undergone Surgery or Radiation Therapy

NCT00054522
View directory record Official record
Conditions
Prostate Cancer
Interventions
calcitriol, dexamethasone
Dietary Supplement · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
2
States / cities
Buffalo, New York • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 8, 2011 · Synced Oct 20, 2026, 2:42 PM EDT
Completed Phase 2 Interventional Results available

Lapatinib in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy

NCT00246753
View directory record Official record
Conditions
Prostate Cancer
Interventions
lapatinib ditosylate
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
3
States / cities
Chapel Hill, North Carolina • Durham, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 28, 2017 · Synced Oct 20, 2026, 2:42 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Reduced Planning Target Volume (PTV) Margins for the Treatment of Prostate Cancer Using the Calypso 4D Localization System

NCT01589939
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
U.S. Army Medical Research Acquisition Activity
Federal
Eligibility
40 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2017
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated May 17, 2016 · Synced Oct 20, 2026, 2:42 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence

NCT02918357
View directory record Official record
Conditions
Prostate Cancer
Interventions
Ga-68 labeled PSMA-11 PET
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Male only
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 2, 2019 · Synced Oct 20, 2026, 2:42 PM EDT
Terminated Phase 1 Interventional Results available

Enzalutamide and Niraparib in the Treatment of Metastatic Castrate-Resistant Prostate Cancer (CRPC)

NCT02500901
View directory record Official record
Conditions
Metastatic Prostate Cancer
Interventions
Enzalutamide, Niraparib
Drug
Lead sponsor
Paul Mathew, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 21, 2019 · Synced Oct 20, 2026, 2:42 PM EDT
Completed Phase 2 Interventional

Study of CEP-701 in Treatment of Prostate Cancer

NCT00081601
View directory record Official record
Conditions
Prostate Cancer
Interventions
CEP-701
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 24, 2012 · Synced Oct 20, 2026, 2:42 PM EDT
Completed Phase 2 Interventional Results available

ET 743 (Yondelis) in Men With Advanced Prostate Cancer

NCT00147212
View directory record Official record
Conditions
Prostate Cancer
Interventions
ET 743
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 18, 2013 · Synced Oct 20, 2026, 2:42 PM EDT
Recruiting No phase listed Observational

Active Surveillance for Cancer of the Prostate (ASCaP)

NCT00949819
View directory record Official record
Conditions
Prostate Cancer
Interventions
Active surveillance
Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
30 Years to 85 Years · Male only
Enrollment
462 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 20, 2026, 2:42 PM EDT
Recruiting No phase listed Observational

Men at High Genetic Risk for Prostate Cancer

NCT03805919
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
30 Years to 75 Years · Male only
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2039
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 20, 2026, 2:42 PM EDT
Recruiting Phase 4 Interventional

Anti-inflammatory Drugs and Serum Prostate-Specific Antigen Test

NCT05629494
View directory record Official record
Conditions
Prostate Cancer, Prostate Inflammation, PSA
Interventions
Ibuprofen 400 mg, TID, PSA test
Drug · Diagnostic Test
Lead sponsor
Albany Medical College
Other
Eligibility
18 Years to 80 Years · Male only
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
3
States / cities
Chicago, Illinois • Albany, New York • Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 18, 2024 · Synced Oct 20, 2026, 2:42 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer

NCT02711956
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Cancer
Interventions
ZEN003694, Enzalutamide
Drug
Lead sponsor
Zenith Epigenetics
Industry
Eligibility
18 Years and older · Male only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
8
States / cities
Los Angeles, California • San Francisco, California • Detroit, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2021 · Synced Oct 20, 2026, 2:42 PM EDT
Recruiting Phase 1 Interventional

Brodalumab in the Treatment of Immune-Related Adverse Events

NCT06673329
View directory record Official record
Conditions
Breast Cancer, Esophageal Cancer, Kidney Cancer, Lung Cancer, Thyroid Cancer, Gynecologic Cancer, Pancreatic Cancer, Stomach Cancer, Brain Tumor, Colon Cancer, Rectal Cancer, Head and Neck Cancer, Oral Cancer, Liver Cancer, Skin Cancer, Prostate Cancer, Testicular Cancer, Solid Tumor
Interventions
Brodalumab, CT scan
Drug · Radiation
Lead sponsor
Brian Henick, MD
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 20, 2026, 2:42 PM EDT
Recruiting Phase 2 Interventional

Using FAPI PET/MRI to Evaluate Prostate Cancer

NCT06675357
View directory record Official record
Conditions
Prostate Cancer Metastatic Disease, Prostate Cancers
Interventions
FAPI, Positron Emission Tomography (PET), Magnetic Resonance Imaging
Radiation · Procedure
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 20, 2026, 2:42 PM EDT
Terminated Phase 1Phase 2 Interventional

To Determine an Effective Dose of VERU-100 for the Treatment of Advanced Prostate Cancer

NCT04843319
View directory record Official record
Conditions
Advanced Prostate Adenocarcinoma
Interventions
VERU-100
Drug
Lead sponsor
Veru Inc.
Industry
Eligibility
18 Years to 100 Years · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
11
States / cities
Tucson, Arizona • San Bernardino, California • San Diego, California + 7 more
Source: ClinicalTrials.gov public record
Updated May 19, 2023 · Synced Oct 20, 2026, 2:42 PM EDT
Completed Not applicable Interventional Results available

Educational Intervention in Increasing Knowledge About Prostate Cancer in High-Risk Neighborhoods

NCT03197896
View directory record Official record
Conditions
Prostate
Interventions
Educational Intervention
Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
40 Years to 69 Years · Male only
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 25, 2026 · Synced Oct 20, 2026, 2:42 PM EDT
Completed No phase listed Observational

Digital PET/CT Using [Ga-68]PSMA vs. [F-18]NaF for Evaluation of Osseous Metastatic Involvement in Prostate Cancer Patients

NCT05527483
View directory record Official record
Conditions
Prostate Cancer
Interventions
[68Ga]PSMA, Flourine-18 [F-18] Sodium Fluoride (NaF), PET/CT
Drug · Diagnostic Test
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Oct 20, 2026, 2:42 PM EDT
Terminated Phase 1 Interventional

Study of Docetaxel Combined with Cirmtuzumab in Metastatic Castration Resistant Prostate Cancer

NCT05156905
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
Cirmtuzumab
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Oct 20, 2026, 2:42 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer

NCT01683994
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Cabozantinib, Docetaxel, Prednisone
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years · Male only
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 8, 2019 · Synced Oct 20, 2026, 2:42 PM EDT
Completed No phase listed Observational

Contrast Enhanced MRI of the Prostate

NCT02245282
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Not listed
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 75 Years · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 17, 2020 · Synced Oct 20, 2026, 2:42 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial)

NCT03787680
View directory record Official record
Conditions
Prostate Cancer
Interventions
Olaparib, AZD6738
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
3
States / cities
Ann Arbor, Michigan • Detroit, Michigan • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 20, 2026, 2:42 PM EDT
Terminated Phase 2 Interventional Results available

Gefitinib and Etoposide in Treating Patients With Advanced Prostate Cancer That Did Not Respond to Hormone Therapy

NCT00483561
View directory record Official record
Conditions
Prostate Cancer
Interventions
Gefitinib plus etoposide
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 120 Years · Male only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Oct 20, 2026, 2:42 PM EDT